Erica accepted the CEO role in October of 2021 after five years leading the finance and operations of the organization. Erica joined Biofrontera Inc. as “employee #2” in the newly formed U.S.-based subsidiary of a German company, with the goal to commercialize the 2015 FDA approved flagship drug Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, in the United States. Starting in 2016, Erica built the business infrastructure to address operations, business logistics, commercial pricing, financial reporting and compliance required to operate a start-up in the U.S. market.
The parent company provided a manual checkbook and the key to a 5,000 sq. foot sublease at the start. Within four months of accepting the keys, Biofrontera had 15 employees and a commercial product on the market in the U.S.
Today Erica leads a team of 90+ employees generating $30 million in revenue. Since company launch, Erica has scaled the business, revised commercial strategies, expanded the salesforce, overseen the merger and integration of another pharma company, led the company through the pandemic, and has grown revenue to record heights. In 2021, Erica led the spin-off and IPO of Biofrontera, Inc. and has raised over $60 million in funding.
In 2019, Biofrontera Inc. expanded its U.S.-product portfolio with the FDA-approved drug Xepi® (ozenoxacin) cream, 1%. Today, Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, the company is fully committed to advancing treatment options and patient care.
With two FDA-approved products and a scalable business strategy, Biofrontera Inc. is ideally positioned for sustainable growth. The company, with Erica in charge, has the goal of becoming a leading U.S. specialty dermatology company by focusing on innovative therapy options that enable dermatology healthcare professionals to help improve the lives of patients.